Table 1.
Patients’ characteristics.
| Characteristics | No. (%) of Patients | CR/PR | SD/PD | p-Value a |
|---|---|---|---|---|
| (n = 41) | (n = 23) | (n = 18) | ||
| Age, years, median (range) | 41 (20–77) | 35 (20–68) | 47 (21–77) | 0.16 |
| Gender | 0.13 | |||
| Male | 22 (54) | 10 (43) | 12 (67) | |
| Female | 19 (46) | 13 (57) | 6 (33) | |
| Grade | 0.40 | |||
| High | 5 (12) | 4 (17) | 1 (6) | |
| Moderate | 14 (34) | 8 (35) | 6 (33) | |
| Low | 15 (37) | 6 (26) | 9 (50) | |
| NA | 7 (17) | 5 (22) | 2 (11) | |
| Tumor location | 0.73 | |||
| Colon | 30 (73) | 16 (70) | 14 (78) | |
| Rectum | 11 (27) | 7 (30) | 4 (22) | |
| Known KRAS status b | 1.0 | |||
| Mutant | 16 (73) | 8 (73) | 8 (73) | |
| Wild-type | 6 (27) | 3 (27) | 3 (27) | |
| Known BRAF status c | 1.0 | |||
| Mutant | 2 (9) | 1 (9) | 1 (9) | |
| Wild-type | 20 (91) | 10 (91) | 10 (91) | |
| Frequency of CD4+ T cells, %, median (range) | 37 (23–61) | 32 (23–51) | 41 (25–61) | 0.013 |
| Frequency of CD4+ T cells, % | 0.01 | |||
| >39.5 | 16 (39) | 5 (22) | 11 (61) | |
| ≤39.5 | 25 (61) | 18 (78) | 7 (39) | |
| Frequency of CD8+ T cells, %, median (range) | 27 (12–53) | 28 (15–53) | 24 (12–46) | 0.24 |
| Ratio of CD4/CD8, %, median (range) | 1.3 (0.5–4.6) | 1.1 (0.5–2.3) | 1.9 (0.6–4.6) | 0.12 |
| Ratio of CD4/CD8, % | 0.03 | |||
| >1.64 | 15 (37) | 5 (22) | 10 (56) | |
| ≤1.64 | 26 (63) | 18 (78) | 8 (44) | |
| CEA, ng/ml, median (range) | 9.3 (1.1–754.6) | 5.0 (1.4–754.6) | 44.0 (1.1–596.1) | 0.03 |
| CRP, mg/L, median (range) | 14.4 (0.2–201.7) | 12.5 (0.2–201.7) | 16.3 (0.5–181.8) | 0.47 |
| LDH, U/L, median (range) | 197.2 (130.9–931.2) | 171.9 (135.5–931.2) | 228.0 (130.9–567.3) | 0.19 |
| Neutrophils, 10E9/L, median (range) | 4.1 (0.6–20.7) | 3.3 (0.6–10.9) | 4.7 (1.2–20.7) | 0.17 |
| Lymphocytes, 10E9/L, median (range) | 1.3 (0.3–2.8) | 1.3 (0.3–2.2) | 1.3 (0.5–2.8) | 0.88 |
| NLR, median (range) | 3.3 (0.6–26.0) | 2.9 (0.6–26.0) | 3.6 (1.0–17.6) | 0.34 |
| Monocytes, 10E9/L, median (range) | 0.6 (0.2–1.8) | 0.5 (0.2–1.8) | 0.6 (0.3–1.0) | 0.72 |
| Platelets, 10E9/L, median (range) | 272.0 (111.6–479.7) | 265.0 (111.6–444.0) | 276.9 (126.0–479.7) | 0.82 |
| PLR, median (range) | 180.5 (61.5–900.0) | 180.5 (61.5–900.0) | 182.7 (66.8–622.4) | 0.94 |
| LMR, median (range) | 2.1 (0.5–9.3) | 2.1 (0.5–9.3) | 2.2 (1.1–7.7) | 0.81 |
| ALB, g/L, median (range) | 40.8 (23.0–49.5) | 40.9 (26.4–49.5) | 40.5 (23.0–48.1) | 0.62 |
| CHO, mmol/L, median (range) | 4.4 (3.4–6.8) | 4.8 (3.5–6.8) | 4.0 (3.4–5.2) | 0.45 |
| TG, mmol/L, median (range) | 1.2 (0.5–3.9) | 1.1 (0.7–3.9) | 1.4 (0.5–3.4) | 0.79 |
| HDL, mmol/L, median (range) | 1.2 (0.5–5.1) | 1.3 (0.6–5.1) | 1.1 (0.5–1.7) | 0.11 |
| LDL, mmol/L, median (range) | 2.8 (0.8–7.7) | 2.8 (1.2–3.8) | 2.4 (2.0–7.7) | 0.63 |
| ApoA1, g/L, median (range) | 1.2 (0.3–1.7) | 1.2 (0.7–1.7) | 1.1 (0.3–1.5) | 0.29 |
| ApoB, g/L, median (range) | 0.8 (0.4–1.5) | 0.9 (0.4–1.5) | 0.8 (0.4–1.2) | 0.45 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CEA, carcinoembryonic antigen; CRP, C-reactive protein; LDH, lactate dehydrogenase; ALB, albumin; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; CHO, cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B.
a
p-Values were estimated by Fisher’s exact test and Mann–Whitney U test for categorical variables and continuous variables, respectively.
b
A total of 22 patients were tested with KRAS.
c
A total of 22 patients were tested with BRAF.